Trial Profile
MDX-CTLA4 [ipilimumab] combined with IL-2 for patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Interleukin-2
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2005 New trial record.